Biotech Watch

complete, accurate, and up-to-date information on publicly traded biotechnology companies

Biotech Watch Home
 

Welcome to Biotech Watch

BiotechWatch provides unbiased, accurate, and timely information concerning the biotech industry, with the goal of creating a web-based community for the exchange of ideas around biotech investing and drug development.

We offer the following three levels of access to biotech information:

  • Premium Access
  • Our Premium database offers an in-depth coverage of biotechnology companies in the sector, giving users the ability to search and sort based on more than 20 parameters including cash on hand, burn rate, clinical trial status, pending milestones, and medical indication. The database is continuously updated every 20 minutes to provide you with complete, most accurate, and up-to-date information.




    More Details

  • Clinical Trial Access
  • Our Clinical Trial database offers disease-specific and biotechnology sector-wide clinical trial information. This database allows the user to point and click on over 200 diseases or 20 medical specialties to identify biotech products under development and their associated biotech companies. If you're looking for the fastest and safest way to find treatments, the BiotechWatch Clinical Trial database allows you to narrow down companies based on their clinical trials.

    More Details

  • Customized Access
  • Our Customized Access searches the entire publicly traded biotechnology sector, accessing clinical and financial information across 500 companies via a simple point and click. Searches include biotech companies selling at or near cash, biotech companies with upcoming clinical or regulatory milestones in the next twelve months, biotech companies selling at 52 week lows or highs, and many more.




    More Details

In addition, we offer the following unique services:
  • Knowledge Base - We provide access to a comprehensive library of documents and resources provided by the National Institutes of Health.
  • Forum - We provide an easy and efficient means for biotech investors to exchange witty ideas in an effort to maximize their profitability. The Forum is a place where new and compelling biotech investments and significant advances in biotechnology are discussed in detail.
  • Real Time Vote Tally
  • Cephalon's Treanda has a 10/31/2008 PDUFA date. Will the FDA approve Treanda for non-Hodgkin’s Lymphoma?
  • Answer
  • Votes
  • Yes, full market approval
  • 1
  • No, FDA will not approve
  • 1
  • Will receive approvable letter
  • 2
 
  • Biotech News
Cell Therapeutics announced that the Company intends to request a hearing with the NASDAQ Listing Qualifications Panel to present a plan for regaining compliance with... Lorus Therapeutics submitted written notice to the NYSE Alternext U.S., LLC (NYX) (formerly American Stock Exchange) of its intention to voluntarily delist its common shares... PDL BioPharma announced the election of Paul W. Sandman and John P. McLaughlin to the company's board of directors. Mr. Sandman served as Boston Scientific... Angiotech Pharmaceuticals reported that its corporate partner, Boston Scientific has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS... XTL Biopharmaceuticals announced the results of its Extraordinary General Meetings (EGMs). The outcome of the EGMs was as follows: all of the resolutions passed and... Genmab announced it has reached the sixth milestone for ofatumumab (HuMax-CD20) under the terms of its collaboration with GlaxoSmithKline (GSK). A milestone payment of approximately... FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Dec. 10, 2008 to review an NDA from Acusphere for Imagify perflubutane polymer microspheres as... Invitrogen announced the introduction of a new benchtop instrument, Countess automated cell counter, which offers a new method of automated cell counting to replace manual... Medicis announced the U.S. Food and Drug Administration (FDA) has approved its premarket approval application (PMA) supplement, based on clinical data which highlights RESTYLANE's duration... Biodel will meet with officials from the U.S. Food and Drug Administration's (FDA) Division of Metabolic and Endocrine Drug Products by the end of January... EpiCept filed a shelf registration to periodically sell up to $50 million in common and preferred stock, convertible debt securities, warrants and units...